Previous 10 | Next 10 |
New Drug Application (NDA) for zuranolone in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) under priority review by U.S. Food and Drug Administration (FDA) with a PDUFA date of August 5, 2023 Sage and Biogen progressing key commercial preparation...
2023-05-01 13:08:06 ET Sage Therapeutics ( NASDAQ: SAGE ) is scheduled to announce Q1 earnings results on Tuesday, May 2nd, before market open. The consensus EPS Estimate is -$2.45 and the consensus Revenue Estimate is $2.33M (+47.5% Y/Y). Over the last 3 months, EPS e...
2023-05-01 08:47:05 ET After three straight sessions of gains, Biogen ( NASDAQ: BIIB ) shares continued to rise in the pre-market Monday as Guggenheim upgraded the biotech citing full FDA approval for its Alzheimer's therapy Leqembi developed with Eisai ( OTCPK:ESALF )( OTCPK:...
2023-04-28 09:00:26 ET Summary Advisory Committee meeting for Biogen's LEQEMBI is set for June 9. Prescription Drug User Fee Act action date is a month later on July 6. Another PDUFA date is August 5 for zuranolone in two indications. Shares of Biogen ( BIIB ) ha...
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and discuss recent business updat...
2023-04-11 16:23:41 ET FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “SAGE POTASH CORP. ANNOUNCES EXPANSION OF LAND PACKAGE IN POTASH-RICH PARADOX BASIN EXPANDING SAGE PLAIN PROJECT IN SOUTHERN UTAH.” SAG...
2023-04-11 09:19:26 ET SAGE POTASH CORP. (TSX-V: SAGE) (“ Sage Potash ” or the “ Company “) is pleased to announce the expansion of its district-scale potash project situated in Utah’s prolific Paradox Basin, known to host extensi...
2023-03-28 16:29:47 ET FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “SAGE POTASH CORP. PARTNERS WITH LEADING GLOBAL ENGINEERING FIRM RESPEC LLC. TO ADVANCE SAGE PLAINS POTASH PROJECT IN SOUTHERN UTAH.” S...
2023-03-27 09:18:34 ET SAGE POTASH CORP. (TSX-V: SAGE) (“ Sage Potash ” or the “ Company “) is pleased to announce its ongoing partnership with RESPEC LLC. (“RESPEC”), a best-in-class global engineering firm specializing in int...
2023-03-27 09:01:14 ET FinancialBuzz.com News Commentary New York, NY (3/27/2023) – Potash is an essential nutrient for plants, particularly in the growth and development of their roots. It is a naturally occurring mineral that contains potassium in water-soluble form, an...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business ...
2024-06-20 13:15:04 ET Scotiabank analyst issues UNDERPERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : HO...